SNTI Stock Summary and Trading Ideas (Senti Biosciences Holdings | NASDAQ:SNTI)

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Senti Biosciences Holdings trades on the NASDAQ stock market under the symbol SNTI.

As of June 5, 2026, SNTI stock price declined to $0.97 with 222,388 million shares trading.

SNTI has a beta of 2.43, meaning it tends to be more sensitive to market movements. SNTI has a correlation of 0.11 to the broad based SPY ETF.

SNTI has a market cap of $30.07 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, SNTI traded as high as $16.94 and as low as $.77.

The top ETF exchange traded funds that SNTI belongs to (by Net Assets): VTI, VXF, IWC.

SNTI has underperformed the market in the last year with a price return of -72.9% while the SPY ETF gained +25.6%. SNTI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.9% and -2.2%, respectively, while the SPY returned +8.5% and -1.1%, respectively.

SNTI support price is $.95 and resistance is $1.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNTI shares will trade within this expected range on the day.